2019 Nobel for Medicine awarded to 3 scientists for work on cell research

Stockholm: Thomas Perlmann, far right, Secretary-General of the Nobel Committee announces the 2019 Nobel laureates in Physiology or Medicine during a news conference in Stockholm, Sweden, Monday Oct. 7, 2019.
Two scientists from the United States and one from Britain won the 2019 Nobel Medicine Prize on Monday for finding how cells adapt to fluctuating oxygen levels, paving the way for new strategies to fight diseases such as anaemia and cancer.

The Nobel award-giving body said US-born researchers William Kaelin and Gregg Semenza shared the prize equally with Peter Ratcliffe, who was born in Britain.

"The seminal discoveries by this year's Nobel laureates revealed the mechanism for one of life's most essential adaptive processes," the Nobel Assembly at Sweden's Karolinska Institute said in a statement on awarding the prize of 9 million Swedish crowns ($913,000).

Their research established the basis for the understanding of how oxygen levels affect cellular metabolism and physiological functions, the institute said.

 
"Oxygen sensing is central to a large number of diseases," it said. "Intense ongoing efforts in academic laboratories and pharmaceutical companies are now focused on developing drugs that can interfere with different disease states by either activating, or blocking, the oxygen-sensing machinery." Medicine is the first of the Nobel Prizes awarded each year.

The prizes for achievements in science, peace and literature have been awarded since 1901 and were created in the will of dynamite inventor and businessman Alfred Nobel.

Nobel medicine laureates have included scientific greats such as Alexander Fleming, the discoverer of penicillin, and Karl Landsteiner, who identified separate blood types and so enabled safe transfusions to be widely introduced.

Last year American James Allison and Japanese Tasuku Honjo won the prize for discoveries about how to harness the immune system in cancer therapies.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel